Absci (ABSI) Stock Overview
A clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ABSI Community Fair Values
Create NarrativeSee what 43 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Absci Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.98 |
| 52 Week High | US$5.23 |
| 52 Week Low | US$2.24 |
| Beta | 2.01 |
| 1 Month Change | 65.83% |
| 3 Month Change | 66.39% |
| 1 Year Change | 64.19% |
| 3 Year Change | 279.77% |
| 5 Year Change | n/a |
| Change since IPO | -76.96% |
Recent News & Updates
Recent updates
We Think Absci (NASDAQ:ABSI) Needs To Drive Business Growth Carefully
Apr 04
Absci Corporation: Drawing Potential Insights On ABS-101 And ABS-201
Jan 29Does Absci (NASDAQ:ABSI) Have A Healthy Balance Sheet?
Jul 19Absci Looks Cheap And Positioned For Growth With AMD's AI Backing
Jan 13Absci Corporation: Struggling To Live Up To Its AI Promise
Nov 20Is Absci (NASDAQ:ABSI) A Risky Investment?
Nov 13Absci: Embryonic Pipeline Looks Expensive Relative To Peers
Oct 29Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile
Oct 03Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships
Jul 28Is Absci (NASDAQ:ABSI) A Risky Investment?
Jun 17Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula
May 16Absci: Differentiated Antibody Discovery Play
Feb 27Shareholder Returns
| ABSI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 25.3% | -2.2% | 0.6% |
| 1Y | 64.2% | 30.4% | 28.7% |
Return vs Industry: ABSI exceeded the US Biotechs industry which returned 27.9% over the past year.
Return vs Market: ABSI exceeded the US Market which returned 27.6% over the past year.
Price Volatility
| ABSI volatility | |
|---|---|
| ABSI Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ABSI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ABSI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 140 | Sean McClain | www.absci.com |
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities.
Absci Corporation Fundamentals Summary
| ABSI fundamental statistics | |
|---|---|
| Market cap | US$732.16m |
| Earnings (TTM) | -US$115.18m |
| Revenue (TTM) | US$2.80m |
Is ABSI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABSI income statement (TTM) | |
|---|---|
| Revenue | US$2.80m |
| Cost of Revenue | US$80.72m |
| Gross Profit | -US$77.92m |
| Other Expenses | US$37.27m |
| Earnings | -US$115.18m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 07, 2026
| Earnings per share (EPS) | -0.74 |
| Gross Margin | -2,782.79% |
| Net Profit Margin | -4,113.68% |
| Debt/Equity Ratio | 0.5% |
How did ABSI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 11:22 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Absci Corporation is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ryskin | BofA Global Research |
| Vamil Divan | Guggenheim Securities, LLC |
| null null | Guggenheim Securities, LLC |